Morgan Stanley Reiterates Buy Rating for PHVS
Morgan Stanley maintains its positive outlook on PHVS with a $46 price target, a 38.18% upside from the current price.
Key Points
- Morgan Stanley reiterated its buy rating for PHVS on June 25, 2026, with a target price of $46.
- Morgan Stanley's $46 price target implies 38.18% upside from Pharvaris N.V.'s ($PHVS) current $33.29 share price.
- PHVS shares traded near $33.29 on Thursday, reflecting market interest in the company's prospects.
- Insider transactions at PHVS included selling by the Chief Medical Officer and CEO in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley has reaffirmed its confidence in PHVS, maintaining a buy rating and setting a price target of $46. This move by analyst Matthew Harrison on June 25, 2026, underscores Morgan Stanley's positive outlook on the company's future performance.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in PHVS
General Atlantic, L.P. held steady with 8,031,252 shares, valued at approximately $226.9 million. FMR LLC slightly reduced its position by 114,686 shares, ending with about 6,284,472 shares valued at $177.5 million, a 1.8% decrease. Foresite Capital Management IV, LLC maintained its holdings at 4,778,581 shares, worth $134.9 million. Venbio Partners LLC also kept its stake unchanged with 4,639,304 shares, valued at $131.1 million. Viking Global Investors LP held steady at 3,653,310 shares, with a value of $103.2 million.
Pharvaris N.V. Stock Down 5.7%
Shares of PHVS traded near $33.29 on Thursday. The stock has seen varied interest from institutional investors, as reflected in recent trading activity. Although specific market cap and P/E ratio data weren't provided, the stock's recent trading price indicates ongoing investor engagement.
$PHVS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Pharvaris N.V.
In June 2026, several insider transactions were reported at PHVS. Lu Peng, the Chief Medical Officer, sold 300 shares at $34.00 on June 18 under a planned transaction and bought 300 shares at $2.59 on the same day. Additionally, Berndt Modig, the CEO, sold 2,291 shares at an average price of $31.07 on June 15 in a planned sale. Peng also sold smaller amounts on June 12 and 11 at prices of $32.20 and $31.51, respectively.
Analysts Set New Price Targets
On June 25, 2026, Morgan Stanley maintained its buy rating for PHVS with a $46 price target. Other analysts have also shown interest: Citizens maintained a buy rating with a $74 target on May 13, 2026, and Wolfe Research initiated coverage with a buy rating and a $42 target on April 9, 2026. The consensus among analysts remains positive, with a strong buy recommendation and a mean target price reflecting optimism for PHVS's future.
Bottom Line
Morgan Stanley's reiterated buy rating for PHVS with a $46 target highlights ongoing institutional interest in the company. While insider sales were noted, these are part of planned transactions and do not necessarily indicate a negative outlook. Investors continue to watch PHVS closely, as reflected in recent analyst ratings and institutional holdings.
Get Pharvaris N.V. alerts
New 13F filings, insider trades, and analyst moves on $PHVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.